Sanara MedTech Q3 revenue up 35% to $21.7M, net loss widens to $2.9M

Sanara MedTech Inc.

2024-Q3 EPS reported -$0.96 revenue$60,367,060

Net revenue rose 35% YoY to $21.7M; net loss of $2.9M vs $1.1M loss in Q3 2023.
Adjusted EBITDA improved to $0.8M from $0.3M in prior-year quarter.
Appointed Keith Myers (former LHC Group CEO) to the board; invested $5.0M in ChemoMouthpiece for 6.64% stake and exclusive U.S. distribution.
Products now sold in over 1,200 facilities; contracted in 4,000+ hospitals; distributor network expanded to 300+.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.